SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with
progression of disease will cross over to open label abemaciclib.
Phase:
Phase 3
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration